Últimas noticias sobre Northann (AMEX:NCL) Bolsa

Northann

Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.

Earnings

News

NAUT

Nautilus Biotechnology Q2 2025 EPS $(0.12) Beats $(0.15) Estimate

BIGC

BigCommerce Rebrands As Commerce.com, Unifies BigCommerce, Feedonomics And Makeswift To Power AI-Driven Agentic Commerce; Nasdaq Ticker Changes From BIGC To CMRC On August 1

FY2025 and Subsequent Highlights
<ul>
<li>Revenues of $142.1 million, up 45.7% from the prior year period</li>
<li>Gross Margin of 15.0% compared to 13.7% in FY2024</li>
<li>Net income of $5.0 million grew 350% compared to net loss of $2.0 million in FY2024</li>
<li>EBITDA of $10.8 million increased 980% compared to $1.0 million in FY2024</li>
</ul>

GCL Global Holdings Reported FY25 Revenue Of $142.1M, Up 45.7% YoY, EPS Of $0.05

GLXY

GK8 Launches Seamless And Compliant Access To Solana DeFi For OTC Desks, Asset Managers, And Regulated Institutions

Foraco Intl (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FAR#TSX">FAR</a>) reported quarterly earnings of $0.06 per share. This is a 18.18 percent decrease over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $69.063 million, this is a 11.33 percent decrease over sales of $77.884 million the same period last year.

Earnings Misses

TSX:FAR

Foraco Intl Q2 EPS $0.06 Down From $0.08 YoY.

Mercedes-Benz Group AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MBGAF#OTC">MBGAF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MBGYY#OTC">MBGYY</a>) has scaled back EV sales in the U.S. and stopped taking new orders, citing low customer demand.
What Happened: The decision affects all variants of the EQS Sedan, EQS SUV, as well as the EQE Sedan and SUV, Business Insider reported <a href="https://www.businessinsider.com/mercedes-benz-electric-vehicle-deliveries-low-demand-trump-tax-credit-2025-7">on</a> Thursday.
Citing a spokesperson for the German automaker, the report suggests that the decision comes after sales for the EVs fell over 25% YoY in the U.S. to 35,027 units compared with last year's 45,843 units.
The automaker has a plant in the state of Alabama as well as one in South Carolina. Mercedes manufactures the EQS and the EQE SUV in Alabama. The report also suggests the company hasn't yet disclosed when orders will be reopened.
During an earnings call with the investors, officials from Mercedes-Benz said that the Trump administration's decision to take away the $7,500 federal EV credit won't have an adverse impact on EV demand as a whole.
"In spite of the announcement that they would take the 7,500 credit away, we don&#8217;t believe that the BEV demand in the United States goes to zero," an official said, adding that the demand may creep upward more slowly than expected.
Why It Matters: The news comes as EV sales in the <a href="https://www.benzinga.com/markets/tech/25/07/46436501/ev-prices-drop-2-8-in-june-as-incentives-surge-amid-tumbling-tesla-sales">U.S. shrank 6%</a> and fell behind other regions like China, where <a href="https://www.benzinga.com/markets/tech/25/07/46408472/electric-vehicle-sales-soar-worldwide-in-june-us-falls-behind-amid-trumps-incentive-rollbacks-report">sales grew 24%</a> in June as the Trump administration announced the axing of EV-related incentives.
Companies like Panasonic Holdings Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PCRFF#OTC">PCRFF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PCRHY#OTC">PCRHY</a>) also scaled back plans to <a href="https://www.benzinga.com/markets/tech/25/07/46362407/tesla-sales-slump-prompts-panasonic-to-delay-4-billion-us-battery-plant-expansion-report">ramp up operations</a> at its battery manufacturing facility, citing poor sales in the U.S. experienced by its client, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
In a series of pro-gasoline decisions, the Trump administration also announced a proposal to rescind the <a href="https://www.benzinga.com/news/politics/25/07/46714902/trump-epa-wants-to-overturn-2009-endangerment-finding-that-controls-carbon-emissions-to-end-16-years-of-uncertainty-for-automakers">2009 Endangerment Finding</a>, which has been used as a basis for many emissions norms currently in place.
Repealing the finding could leave no legal pressure on automakers to maintain emission standards, as well as relaxing the CAFE or Corporate Average Fuel Economy norms <a href="https://www.benzinga.com/markets/tech/25/07/46258669/tesla-made-2-76-billion-from-zev-credits-in-2024-in-us-but-trumps-tax-bill-just-killed-this-revenue-stream">could relieve pressure</a> on the companies to invest in electric vehicles.
Elsewhere, the Trump administration reached a deal with the European Union, with the U.S. imposing <a href="https://www.benzinga.com/news/politics/25/07/46679465/trumps-eu-trade-deal-an-act-of-submission-says-french-pm-its-a-dark-day">15% tariffs on goods</a> imported into the country from the EU, lower than the 30% tariffs supposed to kick in from August 1.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46746057/ford-ceo-warns-of-2-billion-hit-from-trump-tariffs-in-2025-despite-q2-earnings-surge-says-levies-need-to-be-simplified">Ford CEO Warns Of $2 Billion Hit From Trump Tariffs In 2025 Despite Q2 Earnings Surge, Says Levies Need To Be Simplified</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

MERCEDES BENZ GROUP AG by Mercedes Benz Group AG

MBGAF

MERCEDES-BENZ UNSP / ADR by Mercedes Benz Group AG

MBGYY

PCRFF

PCRHY

TSLA

Mercedes-Benz Scales Back EVs In The US, Stops Taking New Orders Citing Low Demand

In addition to the PRIME designation, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the EU Orphan Drug Designation (ODD) application for BGB-16673 in WM. A final decision is anticipated in the coming weeks. The U.S. Food and Drug Administration (FDA) also granted Fast Track Designation to BGB-16673 for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and adult patients with R/R mantle cell lymphoma (MCL).
The EMA's CHMP granted PRIME designation to BGB-16673 based on data demonstrating its novel mechanism and anti-tumor activity in B-cell malignancies. The CHMP recognized the limited treatment options available for WM patients post-BTK inhibitor therapy and acknowledged the strong biological rationale and promising clinical data for BGB-16673 in this setting, thereby demonstrating the potential to address the unmet medical need

Biotech

Large Cap

Health Care

General

The European Medicines Agency Has Granted PRIority MEdicines (PRIME( Designation To BeOne Medicines' Investigational Bruton's Tyrosine Kinase Degrader, BGB-16673, For Waldenstrom's Macroglobulinemia Previously Treated With A BTK Inhibitor

Instil Bio Notes That ImmuneOnco Reported 80% Partial Response In Squamous NSCLC From Phase 2 Trial Of PD-L1xVEGF Bispecific IMM2510 With Chemo; No Dose-Limiting Toxicities Observed

Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) affirms FY2025 Adj EPS guidance from $2.19-$2.29 to $2.19-$2.29 vs $2.24 analyst estimate. Narrows FY2025 sales outlook from $1.650 billion-$1.715 billion to $1.655 billion-$1.680 billion vs $1.667 billion estimate.

Guidance

IART

Integra Lifesciences Affirms FY2025 Adj EPS Guidance of $2.19-$2.29 vs $2.24 Est; Narrows FY2025 Sales Guidance from $1.650B-$1.715B to $1.655B-$1.680B vs $1.667B Est

Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) is looking for Q3 Adj EPS of $0.40-$0.45 vs $0.58 analyst estimate. sees sales of $410.000 million-$420.000 million vs $418.831 million analyst estimate.

Integra Lifesciences Sees Q3 Adj EPS $0.40-$0.45 vs $0.58 Est; Sees Sales $410.000M-$420.000M vs $418.831M Est

Air Products Narrows FY2025 Adj EPS Guidance from $11.85-$12.15 to $11.90-$12.10 vs $11.98 Est

KBR Is Lowers Long-term 2027 Financial Targets: Sets Revenue Target To $9B (Prior Target: $11.5B); Sees Operating Cash Glows Of $650M+ (Prior Target: $700M+)

Titan Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWI#NYSE">TWI</a>) sees Q3 sales of $450.000 million-$475.000 million vs $464.801 million analyst estimate.

Titan Intl Sees Q3 Sales $450.000M-$475.000M vs $464.801M Est

Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) affirms FY2025 Adj EPS guidance from $3.75-$3.85 to $3.75-$3.85 vs $3.81 analyst estimate..

Xcel Energy Affirms FY2025 Adj EPS Guidance of $3.75-$3.85 vs $3.81 Est

Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.43 by 4.17 percent. This is a 28.57 percent decrease over earnings of $0.63 per share from the same period last year. The company reported quarterly sales of $415.605 million which beat the analyst consensus estimate of $395.067 million by 5.20 percent. This is a 0.61 percent decrease over sales of $418.175 million the same period last year.

Earnings Beats

Integra Lifesciences Q2 Adj. EPS $0.45 Beats $0.43 Estimate, Sales $415.605M Beat $395.067M Estimate

Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.66 by 12.95 percent. This is a 38.89 percent increase over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $3.287 billion which beat the analyst consensus estimate of $3.225 billion by 1.91 percent. This is a 8.55 percent increase over sales of $3.028 billion the same period last year.

Xcel Energy Q2 EPS $0.75 Beats $0.66 Estimate, Sales $3.287B Beat $3.225B Estimate

Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) reported quarterly earnings of $2.86 per share which beat the analyst consensus estimate of $2.61 by 9.75 percent. This is a 12.16 percent increase over earnings of $2.55 per share from the same period last year. The company reported quarterly sales of $2.261 billion which beat the analyst consensus estimate of $2.234 billion by 1.19 percent. This is a 0.18 percent decrease over sales of $2.265 billion the same period last year.

Willis Towers Watson Q2 Adj. EPS $2.86 Beats $2.61 Estimate, Sales $2.261B Beat $2.234B Estimate

Titan Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWI#NYSE">TWI</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.03 by 158.82 percent. This is a 120 percent decrease over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $460.830 million which missed the analyst consensus estimate of $478.026 million by 3.60 percent. This is a 13.41 percent decrease over sales of $532.170 million the same period last year.

Titan Intl Q2 Adj. EPS $(0.02) Misses $0.03 Estimate, Sales $460.830M Miss $478.026M Estimate

Cenovus Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVE#NYSE">CVE</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.20 by 65 percent. This is a 15.38 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $8.886 billion which missed the analyst consensus estimate of $9.130 billion by 2.67 percent. This is a 18.41 percent decrease over sales of $10.891 billion the same period last year.

Cenovus Energy Q2 EPS $0.33 Beats $0.20 Estimate, Sales $8.886B Miss $9.130B Estimate

Third Quarter 2025 Outlook
In the third quarter of 2025, the Company expects to generate revenue between $130.0 million and $138.0 million.
The Company expects third quarter 2025 diluted net income per share between $0.17 and $0.25, and non-GAAP diluted net income per share between $0.35 and $0.43.

Comments

Northann

Noticias

Últimas noticias sobre Northann (AMEX:NCL) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL